New insights into dopaminergic receptor function using antisense and genetically altered animals

Annual Review of Pharmacology and Toxicology

Volumn 39, Issue , 1999, Pages 313-341

  Sibley, David R ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Gene targeting; Homologous recombination; Knockout; Oligodeoxynucleotide; Transgenic

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTISENSE OLIGODEOXYNUCLEOTIDE; COMPLEMENTARY RNA; CYCLIC AMP; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DYNORPHIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; RECEPTOR SUBTYPE; SPIPERONE;

DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GENE TARGETING; HYPERPROLACTINEMIA; KNOCKOUT GENE; NEUROPHARMACOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; SCHIZOPHRENIA; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, DOPAMINE;

ANIMALIA;

EID: 0032900952     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.39.1.313     Document Type: Review

References (13)

1. Neve KA, Neve RL. 1997. Molecular biology of dopamine receptors. See Ref. 95, pp. 27-76
2. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: from structure to function. Physiol. Rev. 78(1):189-225
3. Huff RM. 1997. Signaling pathways modulated by dopamine receptors. See Ref. 95, pp.167-92
4. Kebabian JW, Tarazi FI, Kula NS, Baldessarini RJ. 1997. Compounds selective for dopamine receptor subtypes. Drug Discov. Today 2(8):333-40
5. Merchant KM, Gill GS, Harris DW, Huff RM, Eaton MJ, et al. 1996. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist. J. Pharmacol. Exp. Ther. 279(3):1392-403
6. Tallman JF. 1998. NGD 94-1: a specific dopamine-4-receptor antagonist. In Advances in Pharmacology-Calecholamines Bridging Basic Science with Clinical Medicine, ed. DS Goldstein, G Eisenhofer, R McCarty, 42:490-92. New York: Academic
7. Rohrer DK, Kobilka BK. 1998. Insights from in vivo modification of adrenergic receptor gene expression. Annu. Rev. Pharmacol Toxicol. 38:351-73
8. Rohrer DK, Kobilka BK. 1998. G proteincoupled receptors: functional and mechanistic insights through altered gene expression. Physiol Rev. 78:35-52
9. Weiss B, Davidkova G, Zhang S-P. 1997. Antisense strategies in neurobiology. Neurochem. Int. 31:321-48
10. Capecchi MR. 1994. Targeted gene replacement. Sci. Am. 270:52-59
11. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 271:1462-70
12. Weiss B, Zhang S-P, Zhou L-W. 1997. Antisense strategies in dopamine receptor pharmacology. Life Sci. 60(7):433-55
13. 5 dopamine receptors in locomotion revealed by selective antisense oligonucleotides. NeuroReport 9:1-5